Main findings from the report:
IP concerns: copycat drugs and reverse-engineered medical products create cautionary barriers to global market entry. Products developed in country often have more patent protection and drive local manufacturing and development strategies.
Price regulations: some governments are introducing protectionist and nationalist policies to strengthen the local pharmaceutical industry by implementing more stringent price regulation on foreign manufacturers.
Shift in growth from mature markets to emerging markets: Emerging economies could generate up to a fifth of global pharmaceutical sales by 2020. This shift creates new developer interest in patient groups, including new growth opportunities for chronic disease indications. Improved regulatory and IP protection promotes innovation, competition, and increased access to safe medications.
Tighter regulatory approval: high profile product withdrawals in recent years have resulted in regulatory bodies such as the FDA and EMEA becoming more rigorous in their approval procedures. This has resulted in longer product approval times, and in some cases delaying product launches. Pharmaceutical companies need to be able to ensure better rates of approval, right from the discovery stage to enjoy market success.
Cost containment pressures: escalating healthcare costs have put pressure on payers to contain pharmaceutical expenditures. There are multiple stakeholders in the R&D/product development process, which includes payers, patients, and pharmacists. As a result, pricing and reimbursement analysis should be taken into consideration earlier on in the R&D process.
This report is available to current London Business School staff, students and faculty from the Frost & Sullivan database located on the A-Z list of library databases via Portal
Photo from Creative Commons: Flickr: nima+